Skip to content

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Cyclops®

Convenient
Reliable
Easy-to-use
Easy-to-carry
Hygienic
Less Cough

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Protected: Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

Month: December 2024

Protected: Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

PureIMS | Posted on December 17, 2024 |

Protected: Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

There is no excerpt because this is a protected post.

Read moreProtected: Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

Filed under: Press release

Search for:

Recent Posts

Cannovex and PureIMS Announce Strategic Co-Development Agreement for Inhaled Cannabinoid Pharmaceuticals
PureIMS secures a European grant to develop a new dry powder inhaler
An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops
Jaap Wieling will present Epinephrine Cyclops® on GAFA
Protected: Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

Recent Comments

Archives

March 2026
September 2025
August 2025
December 2024
September 2024
May 2024
January 2024
September 2023
August 2023
April 2023
November 2022
January 2022
December 2021
December 2020
August 2020
July 2020
May 2020
March 2020
December 2019
October 2019
September 2019

Categories

Press release
Publication
Scientific publication
Status update

Meta

Log in
Entries feed
Comments feed
WordPress.org

Contact Us

Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
E: info@pureims.com

Social media

Linkedin-in Youtube

Inspiration by Patients

© 2026 pureims